We hypothesize that tumor antigens are presented to naïve T-lymphocytes in the gut associated lymphoid tissue of the vermiform appendix to induce differentiation to cytotoxic T cells in patients with PDAC.
ID
Bron
Verkorte titel
Aandoening
Pancreatic ductal adenocarcinoma (PDAC)
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The level of PDAC-specific oncolytic activity of vermiform appendix derived T lymphocytes
Achtergrond van het onderzoek
Pancreatic ductal adenocarcinoma (PDAC) is notorious for its immune-suppressive tumor microenvironment, low numbers of intratumoral cytotoxic T-cells (CTLs) which
are often functionally exhausted and its poor immune checkpoint inhibitor response.
Our preclinical studies performed in immune competent PDAC mouse models have shown that gut associated lymphoid tissue (GALT) represents a potential source for pancreatic cancer specific CTLs that are not functionally suppressed or exhausted.
The APPART single center translational pilot study is designed to investigate the molecular properties and anti-tumor cytolytic function of T-lymphocytes isolated from the vermiform appendix sana of PDAC patients.
The APPART study may open up doors for T-cell transfer therapy and improvement of immune therapy for PDAC.
Doel van het onderzoek
We hypothesize that tumor antigens are presented to naïve T-lymphocytes in the gut associated lymphoid tissue of the vermiform appendix to induce differentiation to cytotoxic T cells in patients with PDAC.
Onderzoeksopzet
Three time points: plasma and PBMCs before appendectomy; mononuclear cells from the appendix; PBMCs after appendectomy
Onderzoeksproduct en/of interventie
Peripheral venous blood draws, appendectomy during standard of care (laparoscopic) surgery, liver and peritoneal biopsies if metastases are visualized during staging laparoscopy
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patients aged 18 years or older with treatment naïve pancreatic ductal adenocarcinoma who will either undergo staging laparoscopy for locally advanced disease, or tumor resection for (borderline) resectable disease.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
prior appendectomy, prior malignancy within the past 5 years, prior chemotherapy or radiotherapy within the past 5 years, pregnancy, participation in the PREOPANC-2 trial.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7553 |
| Ander register | METC Erasmus Medisch Centrum : MEC-2018-1510 |